Filter

Reloading Equipment Primers and Powder for sale

For sale. Local pickup near Denver CO, will not ship
2000 Federal Small Pistol primers in 3 boxes of 1k $80 per thousand, prefer to sell all together
2000 CCI Small Rifle Primers $80 per thousand
1-8 pd hodgdon CFE pistol powder $280
1-8 pd hodgdon TiteGroup powder $280
1-8pd IMR 8208 $35
2-1 pd cans of Alliant 10x reloader $70 for 2 pds
1-1 pd can of IMR SR 7625 powder $35
1-1 pd can of IMR 4350 $35
Will not ship powder or primers, local pickup only

SOLD two S&B 4-16 PMII

Hate to do it but time to let these scopes go.

Schmidt Bender 4-16x50 with the Gen2XL mildot ret, illuminated, CCW turrets, NEAR manufacturing one-piece mount, tenebraex scope caps. i believe i have the box for this scope.

$2900 shipped


Schmidt Bender 4-16x42 with H37 reticle, CCW, illuminated, tenebraex caps. i bought this scope here off the hide and had the illumination installed back into it and the scope was gone through by S&B. Has not been on a gun since then.

$2800 shipped SOLD

PXL_20230325_005522899.jpg
PXL_20230325_005549903.jpg
PXL_20230325_005539472.jpg
PXL_20230325_005530317.jpg


PXL_20230325_005603964.jpg
PXL_20230325_005603964.jpg

PXL_20230325_005603964.jpg

PXL_20230325_010314951.jpg


Through the scope is the H37

Attachments

  • PXL_20230325_010230421.jpg
    PXL_20230325_010230421.jpg
    270.2 KB · Views: 126
  • PXL_20230325_005610963.jpg
    PXL_20230325_005610963.jpg
    702.8 KB · Views: 119
  • Like
Reactions: nn8734

SOLD Nightforce ATACR 7-35 F1 Mil-XT Perfect $2699

$2699.00 shipped lower 48

Mounted in the ARC M-BRACE that I just sold today. No marks from the mounting - all perfect as brand new
I put on my 300N and decided it was more magnification than I want. ZS not set, so you have it as it comes.
I am more of a hunter-shooter and will go with a 4-20 ATACR that I already own.

Includes all accessories, paperwork, boxing, caps, sunshade, tool etc

No trades, thank you


36E7BA5D-78A8-4502-82B8-1525186B82D2.jpeg
C9AA24A8-E473-4E4F-86AF-67964A0E2A40.jpeg
  • Like
Reactions: Savage_308win

Reloading Equipment Free stuff

Have multiple bags of 6MM Creedmoor Brass. Most is LRP. 75 Hornady, 43 Starline, plus assorted other brands with a few quality brands that are Small Rifle Primer. All brass is cleaned.

Note, All Brass is Range Pickup.

Pay shipping and its yours. If you want a part, that’s also fine. I think the picture clearly shows the brands and quantity. I have it and if anyone can use it, I like them to have it.

Also, if one chooses local pickup, then obviously there are no shipping costs, it’s Free.

F8F31766-7458-417B-B2A9-86A7C6D0332E.jpeg


Now for the bait and switch. I have a partial box of Hornady A-Tips. There are 85 bullets in the box, all but one remains untouched in the original packaging. One bullet was seated in a dummy round to check chambering. Cost for the 85 bullets that also includes the polishing cloth is $50.00 plus shipping.

226FAA29-ABD0-49DC-90F5-92488467E9F3.jpeg


Also, I have some assorted 6BR, 6.5x47 and 6.5 PRC cases in small quantities. If anyone wants em, let me know. I’ll get them to you as cheaply as possible.

Firearms Lone Peak, Krieger, Foundation, TS Customs

After kicking around the idea for the last six months or so I’ve decided to list the best rifle I’ve ever owned. I simply don’t have the time to shoot anymore.

Lone Peak Fuzion SA Mag bolt face
Foundation Centurion in black
Krieger 4 groove heavy palma 1/8 @ 28”
Hawkins bottom metal

Barrel was chambered by Travis @ TS
.115 freebore using the 6.5 prc2 reamer

The “2” designation on the reamer is +.002” @ the case web which solves the sticking issue inherent with the SAAMI chamber specs.

Also outfitted with-

Triggertech diamond trigger
Accurate AICS 7 round mag
Hawkins brake (blended & timed @ TS)
AccuTac WB-4 bipod
Foundation bipod mount

The rifle shoots lasers with no pressure issues whatsoever. I run Berger 144gr hybrids on cruise control at 3060fps

$3,500 firm

Sal- 504-813-2904


F4C79D09-21BF-48D7-B639-2EA1B876BC9B.png
2E16CF50-9527-4B18-80E8-B93F1BFF9336.png
E8BEA410-398F-4A62-913C-3FE1A72E54A1.jpeg
F7D9966F-49F7-4991-996D-64ACA679B81A.png
11B3B860-8951-44B3-A053-7BD21404B025.png
58F09954-15C0-41BB-8FD7-8BF0B4674F7C.png

Gravely vs. XMark

I’m gonna need a new mower soon. I have a 23 year old John Deere riding lawn mower. It’s been a damn good mower, I mean a DAMN good mower. But the deck is worn out, the front end is worn out, the hrdrostatic drive is on its last leg, my son tore the cowling, over the motor, up a long time ago, the tires won’t hold air for long, and it needs a new battery…it’s just a mess. The bad thing is, the motor is an excellent motor, and still runs great.
So…I’m gonna break it to the wife that it’s time to get a new mower.

When I retire in a couple years, I’ll be moving, and where I’m moving to has at least 2 acres. So, I’m going to be looking for a ZTR mower.

My limited knowledge about them leads me to either a XMark or a Gravely.
The XMark is obviously the most popular with the lawn care services, and that means a lot to me. It has more electronics on it. Not sure if that’s a good thing or bad. It’s probably more comfortable than the Gravely. I’m sure the XMark is a great machine.

The Gravely has good reviews, seems to be a more simple machine, less electronics, which means easier to work on, and it looks like it’s built like a frikkin tank.

One thing I don’t want is a tin foil machine. A heavy duty deck is a must. A reliable motor and drive are necessary. I don’t want the mower to spend most of its life in the shop.

Anybody have any pros or cons about either machine that they’d care to share? I’d sure love to hear which machine you’d prefer, and your whys and why nots.

It’s going to be $6000-$8000 dollars I’m sure, when it’s all said and done, so I want to make the best decision. I’m going to continue to read reviews before I buy. I just thought I’d get your $0.02 worth as well.
Thanks.

Had an interesting encounter at Lowes.

I was wearing one of my Sniper's Hide sweat shirts, standing in the checkout line at Lowes. As I turned to leave and old guy said, "Hey I like your shirt" I told him I shoot long range and he brightened up and mentioned he was headed up to Raton NM to the NRA Whittington center, had I heard of it? I told him I got certified as a Barrett Armorer there and shot my M82 out to 1000 yrds. He told me he had hit the White Buffalo at 1350 yards and that he was going out to meet up with members of his old team from Viet Nam, headed up by Col. Robert Brown. :cool: We chatted for a moment more then I wished him well and God Bless.

I'm kicking my ass for not inviting him to go shooting, probably could learn a lot.

Marburg is coming!

You guys are going to really need to get this one - this Marburg here has a 90% mortality. Just spread from New Guinea to Tanzania. But NO WORRIES folks, BioNTech, the same awesome innovators that brought us the Covid vaccine with 95% efficacy, has already a superb mRNA Marburg vaccine ready to go as of end of January. Plus, the NIH has done its first human trials in January with Marburg vaccines at Walter Reed.
And - low and behold - an outbreak of Marburg in New Guinea in February just happened!!! What are the odds!!

Published end of January:
https://www.linkedin.com › pulse › vaccine-production-marburg-has-right-stuff-christian-korner

Vaccine production: Marburg has the right stuff​

Christian Korner

Christian Korner​

Head of Pharma Business US at Siemens​

Published Jan 25, 2023
+ Follow
How quickly “normal life” can be resumed depends in part on how quickly the population can be vaccinated. One of the vaccinations that provides particularly good protection against Covid-19 is the BNT162b2 vaccine from Mainz-based biotech company BioNTech SE. To scale-up the manufacturing capacity further, the company began production in Marburg which is one of the largest mRNA-based vaccine manufacturing sites worldwide. To achieve this, BioNTech drew on the expertise available at Siemens to enable it to provide more of the sought-after vaccine as quickly as possible.
BioNTech manufactures BNT162b2 in collaboration with US pharmaceutical specialist Pfizer. The company has started manufacturing in Marburg, in the German state of Hesse. In the fall of 2020, it took over a production facility for biotech products from Novartis for this purpose. That gives it a good basis for successful vaccine production: The plant at Marburg comes with an ultramodern production facility for recombinant proteins. The relevant expertise is also available, since BioNTech also acquired a highly qualified employee base along with the production facility, all of whom are experienced in developing new technologies. The facility in Marburg had been producing influenza vaccines based on flu cell culture, then changed over to recombinant proteins for cancer treatments and now manufactures mRNA vaccine. Siemens is providing support with the switchover to vaccine production. There are two reasons for this: Siemens already knows the Marburg facility very well and has worked with it previously on activities including automation of vaccine production development. The two companies can also look back on a number of projects they have already completed together in the previous years.
No alt text provided for this image

Full speed ahead thanks to total commitment
Everyone involved in the project knew how important it was: The sooner production could start; the sooner more vaccine doses will be available. The hopes of society therefore depend on this project: German Chancellor Angela Merkel even commented at the Federal Press Conference on February 1, 2021, that “Marburg will make the difference.” A project of this magnitude normally takes about a year, but in this case the participants completed the conversion in just five months. Main components of the new manufacturing execution system (MES) were completed in only 2.5 months. Andreas Haag, in charge of the project for Siemens, observes: “One factor that made it possible was the high level of cooperation between the teams and outstanding commitment by everyone involved: They all worked overtime and took no leave in order to advance the project as fast as possible.” And under pandemic conditions, too: Things that would normally be done by working together on-site were instead performed largely by a decentralized team based in separate home offices. The project was a complete success, since the new Electronic Batch Records (eBPR) as part of the manufacturing execution system (MES) was ready to use in just 2.5 months.
What was converted?
During the project to switch the Marburg plant over to production of mRNA-based vaccines, Siemens focused on future viability. All the improvements are Industrie 4.0-compatible. One of the challenges with the conversion was the fact that it involved switching from rigid to mobile production with many single-use components. For example, it meant a whole raft of components had to be registered. That was one reason why the project partners decided to switch to paperless production. At the same time, working with mRNA meant a higher clean room class than was previously required in the facility. Paper is now an avoidable “contamination factor” that doesn’t arise with digital production. That was the basis for opting for the Opcenter Execution Pharma solution from Siemens as the new MES. This solution enables complete paperless manufacturing and fully electronic batch recording. Seamlessly integrating automation solutions makes it possible to develop, optimize, and manage production processes automatically. Because mRNA processes include a lot of manual stages – weighing, for example – operators require guidance through these. This is provided by the workflow management component of the software. Opcenter Execution Pharma orchestrates the various sections of the system to ensure efficient production. The software enables real-time production and the provision and analysis of process and quality information in order to optimize production activities from initial order to finished product.
To automate the facility, all systems were converted to the latest version of Simatic PCS 7. The powerful, flexible, and scalable distributed control system steers and controls all the processes in the plant and takes digitalization to field level. Although most parts of the new MES are now in place, additional automation components are still in progress.
In focus: paperless production
Paperless production offers advantages over traditional procedures in the pharmaceutical industry in particular: Process data, conditions, and results are recorded in detail to ensure processes are more resistant to error, in other words, they are made more robust and less susceptible to deviations. At the same time, the tasks of data input and documentation are now less complex. Electronic Master Batch Record Management enables users to create, execute, review, and release Master Batch Records (MBR), and Electronic Batch Records (eBR) are made faster. The individuals in charge can easily monitor, observe and, if necessary, record every stage of production and every base material. Testing is based on the principle of “review by exception” – in other words, deviations are dealt with when the system recognizes them based on exception rules. That makes the testing process less labor-intensive and much faster, since otherwise the individuals in charge would have to check several thousand pages on paper. As a result, digital production is a significant factor in making the process faster and improving quality.
Unity is strength
To ensure a smooth start to production, Siemens supported the implementation of the system at BioNTech with Hypercare and a 24/7 project-based standby arrangement. That means the employees in production could request help with operating the system from the manufacturer at any time of the day or night. The project is a complete success for both parties and the production was able to start before the end of February with the production of the drug substance: the mRNA. “We want to thank Siemens for their excellent collaboration on this project and the huge effort they put in, often exceeding 100 percent,” says Valeska Schilling, Head of Production Department at BioNTech Marburg.
62

-------------------------------------------------------------------​

Marburg vaccine shows promising results in first-in-human study​

SEM image of rod-shaped Marburg virus particles, colorized blue.
Colorized scanning electron micrograph of Marburg virus particles (blue) both budding and attached to the surface of infected VERO E6 cells (orange).

What​

A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial. The vaccine, developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, could someday be an important tool to respond to Marburg virus outbreaks.

This first-in-human, Phase 1 study tested an experimental MARV vaccine candidate, known as cAd3-Marburg, which was developed at NIAID’s Vaccine Research Center (VRC). This vaccine uses a modified chimpanzee adenovirus called cAd3, which can no longer replicate or infect cells, and displays a glycoprotein found on the surface of MARV to induce immune responses against the virus. The cAd3 vaccine platform demonstrated a good safety profile in prior clinical trials when used in investigational Ebola virus and Sudan virus vaccines developed by the VRC.

MARV, a filovirus in the same family as Ebola virus, causes a rapidly progressive febrile illness that leads to shock and death in a large proportion of infected individuals. Many scientists think that MARV disease outbreaks in humans begin by when the virus makes the jump from its primary animal host, which is likely to be certain chronically infected bats in sub-Saharan Africa. The symptoms of MARV disease are akin to those seen with Ebola virus disease and can include fever, headache, chills, rash, abdominal pain, vomiting, and diarrhea. As the disease progresses, patients may suffer from multiple organ dysfunction, delirium, and significant bleeding from the gastrointestinal tract or other sites that may result in death. No approved vaccines or specific therapies are available for MARV disease, aside from supportive care. While some experimental vaccines have previously been tested, none have proven to be both highly effective and to provide durable protection. In areas of Africa where a vaccine for Marburg is most needed, a single-dose vaccine that could protect recipients over a long period of time would be a crucial part of quelling outbreaks.

In this study, 40 healthy adult volunteers were enrolled at the Walter Reed Army Institute of Research Clinical Trials Center in Silver Spring, Maryland. They received a single dose of either a low dose of the vaccine (1x1010 particle units) or a higher dose (1x1011 particle units). For safety, the volunteers were enrolled in a dose-escalation plan. Three participants received the lower dose. Then, when they did not exhibit severe adverse reactions after the first seven days, the trial proceeded to enroll the remaining 17 volunteers. The same procedure was also used for the higher dose group. Volunteers were monitored for adverse reactions to the investigational vaccine and evaluated at regular intervals for 48 weeks to track their immune responses.

The trial’s safety results were encouraging: There were no serious adverse events, and the experimental vaccine was well-tolerated. One participant in the higher dose group developed a fever following vaccination, but it resolved by the following day. In addition, the investigational vaccine appeared to induce strong, long-lasting immunity to the MARV glycoprotein: 95% of participants in the trial exhibited a robust antibody response after vaccination, and 70% maintained that response for more than 48 weeks.

Plans are in place to conduct further trials of the cAd3-Marburg vaccine in Ghana, Kenya, Uganda, and the United States. If additional data supports the promising results seen in the Phase 1 trial, the cAd3-Marburg virus vaccine could someday be used in emergency responses to MARV outbreaks.

Article​

M Hamer et al. Safety, tolerability, and immunogenicity of the Marburg chimpanzee adenovirus vector vaccine (cAd3-Marburg) in healthy adults: a phase 1, open-label, dose-escalation trial. The Lancet DOI: 10.1016/S0140-6736(22)02400-X (2023).

Who​

Lesia Dropulic, M.D., chief of the Clinical Trials Program at NIAID’s Vaccine Research Center, is available for comment.

Contact​

To schedule interviews, please contact Elizabeth Deatrick, (301) 402-1663, [email protected].

NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
--------------

An outbreak of the deadly Marburg virus has been confirmed. Here's what you need to know​

There is no vaccine or drug treatment for the virus, which has killed at least 9 people in Equatorial Guinea​

Stephanie Hogan · CBC News · Posted: Feb 17, 2023 3:00 AM CST | Last Updated: February 18

MPX_BIRAK_MARBURG_OUTBREAK.jpg


Racing to contain Marburg virus outbreak in Equatorial Guinea​

1 month ago
Duration 2:13
There's a race to contain an outbreak of Marburg disease — caused by an Ebola-related virus — in Equatorial Guinea, where at least nine people have died. There's no cure for the deadly disease and development of a vaccine was paused years ago.
The World Health Organization this week confirmed an outbreak of the Marburg virus in Equatorial Guinea — the first time the tiny country in Central Africa has seen cases of the deadly illness.
Marburg, which is related to Ebola, is already being blamed for at least nine deaths in the country, and another 16 suspected cases are being investigated.
Without treatment, Marburg can be fatal in up to 88 per cent of people.
A 2004-05 outbreak in Angola killed 90 per cent of the 252 confirmed cases.
Here is what you need to know about this rare but dangerous virus.

What is Marburg virus?​

Marburg virus is believed to have originated in African fruit bats. It was first identified in 1967 in Germany and the former Yugoslavia, according to the U.S. Centers for Disease Control and Prevention, among people who had been working with green monkeys that had been imported from Uganda.
According to the World Health Organization (WHO), people can contract the virus through prolonged exposure in mines or caves where the bat colonies live.
The virus spreads between humans through direct contact with blood or other bodily fluids of an infected individual, or with surfaces contaminated with the virus, such as clothing or bed sheets.
Marburg is not airborne.
An African fruit bat hangs upside down in its cage.

Marburg virus is believed to have originated in the African fruit bat, and it can be contracted by humans through prolonged exposure to mines or caves where the animal lives. (Bob Child/The Associated Press)

What are the symptoms?​

Symptoms may begin "abruptly," according to WHO, and include high fever, severe headache and malaise. Muscle aches and pains are also common.
"It can impact every organ, and it essentially will cause a shock-like syndrome," said Dr. Isaac Bogoch, an infectious diseases specialist at Toronto General Hospital.
He said the virus can also cause gastrointestinal complications and a predilection to easy bleeding.
WHO says a rash can appear in the first seven days, and the central nervous system can be affected, resulting in confusion, aggression and irritability.
If death occurs, it generally happens eight to nine days after onset, following severe blood loss and shock.
An electron microscope photo of the Marburg virus.

An electron microscope photo of the Marburg virus. An outbreak of the deadly virus has been confirmed in the Central African country of Equatorial Guinea. (Thomas Geisbert/University of Texas Medical Branch)

How is it treated?​

There is currently no vaccine for Marburg and no therapeutics to treat it. But patients can be helped.
"They need supportive care," Bogoch said, including intravenous fluids, as well as electrolyte balance and monitoring. "That can significantly lower the mortality rate," he said.

Where are the confirmed cases now?​

Cases connected to the current outbreak in Equatorial Guinea were first detected in the northern province of Kie-Ntem, near the border with Cameroon.
The outbreak was confirmed after samples were sent to a lab in Senegal. Suspected cases from Cameroon and Gabon were also investigated but found not to be Marburg, WHO said.
But that doesn't mean there aren't more Marburg cases.
"When new diseases appear in new locations, we are often just seeing a piece of the picture," said Dr. Kamran Khan, the founder and CEO of Toronto-based BlueDot, a company that tracks infectious diseases around the world.
He said there are probably more cases and more contacts than the official numbers would indicate, noting that Equatorial Guinea is one of the most resource limited countries in the world.
"Its capabilities in terms of its health-care system, its public health infrastructure for countering an outbreak, are pretty limited," he said.


WHO said it is sending medical experts to help local officials in Equatorial Guinea, along with protective equipment for hundreds of workers.
"Surveillance in the field has been intensified," said George Ameh, WHO's country representative in Equatorial Guinea.
"Contact tracing, as you know, is a cornerstone of the response. We have ... redeployed the COVID-19 teams that were there for contact tracing and quickly retrofitted them to really help us out."
WHO director general Tedros Adhanom Ghebreyesus said the agency is also supporting the governments of Cameroon and Gabon "to prepare, to rapidly detect, isolate and provide care for any suspected cases."
WATCH | WHO is deploying teams to Equatorial Guinea to deal with Marburg outbreak:

2023-01-31T222359Z_1744133242_RC2Q5Y96O0IR_RTRMADP_3_HEALTH-WHO-CONGO.JPG


Trying to contain the Marburg virus​

1 month ago
Duration 0:56
WHO director general Tedros Adhanom Ghebreyesus says the agency is sending teams and supplies to the Central African country of Equatorial Guinea to try to contain the current outbreak of the deadly Marburg virus.

Is there a concern about spread?​

The current Marburg outbreak appears to be regional, but Bogoch notes that infection on one part of the Earth can quickly land on another part in a very short time frame.
"We saw that with, for example, the West African Ebola virus epidemic — which started off as a very small outbreak, turned into a multi-country, multi-year outbreak that took a long time to get under control."
Khan of BlueDot said Equatorial Guinea is going to need international assistance to be able to get ahead of this outbreak. "Today, it's a concern for the region and some of the neighbouring countries. But if we don't get ahead of this, this could become a broader concern for the global community."

Should people living in Canada be worried?​

There's probably no immediate concern about a case of Marburg being found in Canada.
"I think this is important for Canadians to understand that the likelihood of a case of Marburg showing up in Canada right now is exceedingly low," Kahn said. But he said it's important to be aware of the larger issue — which is that "there are more outbreaks appearing in the world today, they are becoming larger, they are becoming more dangerous and disruptive."
Bogoch said while the current Marburg outbreak is small, now is the time to jump on it so that it doesn't expand.

--------------------------------------------------------
Well, its already to Tanzania, but obviously the Canadian press weren't on top of how our astute virologists saw this coming and were doing the first vaccine clinical trials in January. And the head dude at Siemens was appropriately proud of this as can be seen in his January 25 article above.

Just amazing, almost like these guys had a crystal ball. Thank goodness the WHO is finally (or will be within a week or so) in charge of everything so we don't have to worry about local bureacracies or even the wisdom of supersmart Joe BIden interfering one bit!

SOLD Steiner T6Xi 5-30x56, SCR2 Mil Reticle

I’m selling my T6Xi 5-30x56 with the SCR2-Mil Reticle.

The scope is new… and has not been in rings and mounted. It comes with the original box and all of the goodies.

It’s a very nice scope, but it’s a little too big for what I wanted to do with it.

Asking $1600 shipped. I’m not interested in trades.

If you have any questions or want to see more pics, please let me know.

Thanks for looking, Matt

Attachments

  • 0F09C2B6-4BB0-49E1-90C0-FA8B4D5DC6C7.jpeg
    0F09C2B6-4BB0-49E1-90C0-FA8B4D5DC6C7.jpeg
    365.9 KB · Views: 94
  • 775050BF-0F97-4B7E-9FD4-A21644BC5035.jpeg
    775050BF-0F97-4B7E-9FD4-A21644BC5035.jpeg
    299.4 KB · Views: 87
  • 35E6D796-1168-4A18-8514-C0E94E1BA62E.jpeg
    35E6D796-1168-4A18-8514-C0E94E1BA62E.jpeg
    321.1 KB · Views: 92
  • E23C5D42-8969-4259-A60B-80EDCF981A15.jpeg
    E23C5D42-8969-4259-A60B-80EDCF981A15.jpeg
    391.8 KB · Views: 104
  • 9C11C3D6-71EE-4DFC-B98E-15AA4CCBAABA.jpeg
    9C11C3D6-71EE-4DFC-B98E-15AA4CCBAABA.jpeg
    307.8 KB · Views: 83
  • 5D4A0C9F-6677-47A8-8228-8B7EFDC75C7E.jpeg
    5D4A0C9F-6677-47A8-8228-8B7EFDC75C7E.jpeg
    484.9 KB · Views: 89

France is burnng down....

France is burning down and not hardly a peep of coverage that Ive seen from our media that Ive seen.... they're afraid of it happening here.

Oh please let there be contagion -- torches, tar and ptchforks ... and we remove that senile, evil incesting pedo freak.

Login to view embedded media
Login to view embedded media

NO GUNSMITH Practical Custom Rifle Build

I'm looking to build a practical precision custom rifle under 12lbs for both hunting and NRL Hunter Open Light division competition. I'm looking for suggestions or recommendations on what would make an ideal build for my requirements plus evaluations on what I'm thinking so far. I'm a very longtime hunter and been competing in PRS matches for several years now. I'd like to move into a custom light practical rifle, but am not sure about all the compatibility detail gotchas I might run into, especially since my plan is that it should be a No Gunsmith Required build. We live in the world of prefits now, I'd like to prove that we don't need gunsmiths, bedding compound or shop lathes to build reliable precision bolt action rifles anymore.

Here's my requirements:

- NO GUNSMITHS! I need to be able to assemble this in my garage with basic tools, a torque wrench, a barrel vise/wrench and some gauges and NO STOCK BEDDING COMPOUND and expect it to be within 90% of the potential of a gunsmith-barreled and blueprinted action.
- Chambering suitable for thin skinned north American or African plains game, mostly whitetail and mule deer out to 400y in a commonly available factory chambering. I intend to reload, but for an explicitly practical non-gamer rifle, I'm thinking 6.5 Creedmoor is the best compromise. No barrel burner 6mms.
- Must also be suitable for NRL Hunter Open Light division (under 12lbs total) should NRL Hunter decide to have any matches in Central or South Texas in the future
- As such, its going to need a lighter barrel, I'm thinking 22" Proof carbon fiber Sendero profile.
- Going to need a lighter carbon fiber stock, but here's the trickiest part of my build...it MUST be a traditional stock profile NOT a "modern" AR style pistol grip chassis. Its a practical rifle, not a gamer race gun. Yes, I'm a Fudd at heart and set in my ways about certain things... pistol grip chassis bolt guns are a bridge too far for me. Ideally it should have adjustable LOP (pad spacers ok) and comb, though. In order to stick with the NO GUNSMITHS rule, its probably going to have to be a mini-chassis of some sort, so I'm thinking something like a Manners MCS-LRH with their mini chassis.
- Action and bottom metal needs to be AIAW magazine compatible with a standard integrated 20 moa pic rail. I intend to use AIAW mags exclusively but AICS compatibility would be a nice to have as well. I really like the new ARC Coup de Grace, but I don't know for sure if I can get a truly prefit Proof carbon barrel for it nor an inlet for manners MCS-LRH with mini chassis. NO GUNSMITHS rule trumps all.
- Needs an FFP mil/mil optic appropriate for both hunting (up to 400y) and occasional competition (out to 1200y) but on the lighter side. A Leupold Mark 5HD 3.6-18x44 would make more sense for ultra weight savings but given that I intend to compete with it as well, I think a MARK 5HD 5-25X56 w/PR-2 reticle would be the best compromise.
- Once piece mount. I've given up on two piece rings forever. You won't convince me otherwise. I'll happily eat the weight and shave it somewhere else, even if I gotta dremel it. Its Spuhr or nothing.
- Bipods should be mentioned here I suppose but I don't think they're critical unless I'm so near my 12lb limit that I need something special. I'm pretty partial to my old Arca Harris, but I might be convinced to go Atlas or Spartan Javelin if I have to shave weight. I'm only mentioning it here because its part of NRL Hunter weigh-in.
- I suppose if I have to also mention it for the sake of weight here, I'll say that as long as I can afford the weight, I'll probably put an EC tuner brake on it because I'm lazy and would prefer to tune barrels instead of tune seating depth. Yeah, its a little gamer, but I've seen the light and hate fiddling with seating depth for the sake of group size when I can just dial-a-group, especially if I need to tune for factory ammo.

Any suggestions that meet the criteria or gotchas that I may not have thought of?

Biden Judicial Nominee Exposed as Clueless on Major Due Process Case During Confirmation Hearing!


WASHINGTON, DC – Joe Biden judicial nominee Kato Crews stumbled during his Senate confirmation hearing Wednesday, not knowing one of the most basic constitutional protections for citizens accused of crimes by their government, confusing it with Second Amendment rights, about which he likewise seemed confused.

Biden nominated Crews for a lifetime appointment as a trial judge on the U.S. District Court for the District of Colorado, where he currently serves as a federal magistrate. Previously he was a labor lawyer, making his nomination consistent with Biden’s understanding that big union bosses are the cornerstone of his political coalition and absolutely essential to his running for a second term.

Crews’ confirmation hearing before the Senate Judiciary Committee went off the rails when Sen. John Kennedy (R-LA) asked him, “Do you know what a Brady motion is?”

“It’s not coming to mind at the moment,” Crews responded. “I believe that the Brady case involved something regarding the Second Amendment.”

Crews’ answer is stunning. Brady v. Maryland is a watershed 1963 Supreme Court case which held that it violates the Due Process Clause of the Constitution – which is in both the Fifth and Fourteenth Amendments – when government prosecutors discover evidence that a suspected criminal is innocent, but do not provide a copy of that evidence to the suspect’s lawyer.


Amanda Brailsford, U.S. district judge for the district of Idaho nominee for U.S. President Joe Biden, left, and Kato Crews, U.S. district judge for the district of Colorado nominee for Biden, shake hands during a Senate Judiciary Committee nomination hearing in Washington, DC, US, on Wednesday, March 22, 2023. (Nathan Howard/Bloomberg via Getty)
That is a bedrock criminal procedural right, and the sort of question that recent law school graduates can expect to be on the bar exam to get their law license.

The principal behind Brady is that a primary purpose of the Constitution is to protect citizens against abuse by their own government, and that if prosecutors, with their enormous resources, come across evidence that a person is innocent of wrongdoing, fundamental fairness and justice demand a defense lawyer have full access to that information to bring to the court’s attention.

It is disturbing that any person who as a district judge would wield the power for the rest of his life to send Americans to prison would not know this basic constitutional protection. This becomes even more troubling because as a federal magistrate – who is like an assistant judge serving under a life-tenured district judge – Crews should have had the opportunity to learn about Brady motions, if he didn’t remember about them from law school.

Crews’ answer also raises an entirely separate issue as to why senators might doubt his qualifications to be a judge: not knowing the Second Amendment, which is another fundamental right.

Some constitutional provisions like the First Amendment have scores of Supreme Court cases, a couple dozen of which could be called major. While every American should want every judge to be thoroughly familiar with their First Amendment rights to free speech, freedom of religion, freedom of association, and so on, it is not surprising that a trial judge might not be able to rattle them off citing chapter and verse.

However, there have been only three significant Supreme Court regarding the Second Amendment in all of American history, and they are all recent: District of Columbia v. Heller (2008), McDonald v. Chicago (2010), and New York State Rifle & Pistol Association v. Bruen (2022).

And there are numerous cases involving Bruen in the courts at the moment, in the wake of Justice Clarence Thomas’ opinion where the court held that gun control laws are constitutional only if they are consistent with the historical public understanding of the Second Amendment’s “right to keep and bear arms.”


Molly Silfen, judge for the U.S. Court of Federal Claims nominee for U.S. President Joe Biden, from left, Amanda Brailsford, U.S. district judge for the district of Idaho nominee for Biden, and Kato Crews, U.S. district judge for the district of Colorado nominee for Biden, are sworn in during a Senate Judiciary Committee nomination hearing in Washington, DC, US, on Wednesday, March 22, 2023. ( Nathan Howard/Bloomberg via Getty)
Perhaps Crews confused Brady with Bruen because they sound similar, but that is like a person confusing football with baseball because they both contain the word “ball” or confusing steak with fried chicken because they’re both meat entrees. A person who would make mistakes like those would never be labeled an expert on sports or food, respectively.

This instance of Crews faceplanting on camera is just the latest incident of growing criticism about Biden and his White House picking judicial nominees who are regarded as young, far-left activists chosen for their passion to advance a leftwing view of the law instead of deep knowledge of the Constitution and the temperament to apply the law with fairness and impartiality. Other nominees are criticized because Biden and his team have openly bragged about picking some nominees because they are racial minorities or LGBT, rather than talking about their merits, pandering to different political constituencies to benefit Biden’s party.

The Crews episode brings to mind the hearing of Charnelle Bjelkengren, who did not know what was in Article I of the Constitution, which lays out all the powers of Congress and the issues on which federal laws can be passed, or Article II of the Constitution, which defines the powers and duties of the U.S. president.

The Senate Judiciary Committee has not yet scheduled a vote on the Crews nomination.

Is a NEW Tikka T3x stainless action & trigger worth $985?

Locally I can get a new Tikka T3x Lite Stainless rifle in Left Hand chambered in .308 for about $985 including tax...

But I just want the action and trigger out of it so I can build a 6.5 CM, chassis based rifle...

The question: Is the Stainless TIkka T3x complete action, and trigger assembly, worth the $985?

What are the most reliable mags and chassis combo, to run with a T3x action? I'd really prefer metal A.I. mags, or something similarly durable, but want max feeding reliability.